Niamh Madigan | 02/26/2013
Sonia Poli, VP for Non Clinical Development at Addex Therapeutics, a small biotech built in Geneva explains how the new FDA and EMA guidelines will impact their business. She looks at the daily challenges they are faced with and stresses the importance of having highly valuated assays which will translate into clinical data.
Have Your Say
Rate this feature and give us your feedback in the comments section below
To continue reading this story Click Here
RECOMMENDED
Upcoming Events
GenAI Life Science & Health 2025
September 1 - 3, 2025
Berlin, Germany
Register Now |
View Agenda |
Learn More
DigIT Pharma AI Commercial Excellence & Health 2025
September 1 - 3, 2025
Palace Hotel Berlin, Germany
Register Now |
View Agenda |
Learn More